Page last updated: 2024-12-04

fosmidomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fosmidomycin: from Streptomyces lavendulae; RN given refers to parent cpd; structure in second source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fosmidomycin : Propylphosphonic acid in which one of the hydrogens at position 3 is substituted by a formyl(hydroxy)amino group. An antibiotic obtained from Streptomyces lavendulae, it specifically inhibits DXP reductoisomerase (EC 1.1.1.267), a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID572
CHEMBL ID203125
CHEBI ID443725
SCHEMBL ID301404
MeSH IDM0083078

Synonyms (39)

Synonym
3-(n-formyl-n-hydroxyamino)-propylphosphonic acid
3-[formyl(hydroxy)amino]propylphosphonic acid
fr-31564
3-(formyl-hydroxy-amino)propylphosphonic acid
FOM ,
fosmidomycin
DB02948
fosmidomycine
3-(n-hydroxyformamido)propylphosphonic acid
CHEBI:443725 ,
66508-53-0
fosmidomycinum
{3-[formyl(hydroxy)amino]propyl}phosphonic acid
fosmidomycina
[3-(formyl-hydroxy-amino)-propyl]-phosphonic acid
bdbm50153713
CHEMBL203125 ,
AKOS006272014
(3-(n-hydroxyformamido)propyl)phosphonic acid
fosmidomycina [inn-spanish]
(3-(formylhydroxyamino)propyl)phosphonic acid, monosodium salt
5829e3d9i9 ,
fosmidomycine [inn-french]
fosmidomycinum [inn-latin]
unii-5829e3d9i9
fosmidomycin [inn]
NCGC00264107-01
fosmidomycin [mart.]
fosmidomycin [mi]
SCHEMBL301404
GJXWDTUCERCKIX-UHFFFAOYSA-N
3-(n-formyl-n-hydroxyamino)propylphosphonic acid
fosmidomycin sodium salt hydrate
DTXSID70216712
[3-(n-hydroxyformamido)propyl]phosphonic acid
Q905038
gtpl9739
3-(formyl-hydroxyamino)propylphosphonic acid
NCGC00264107-02

Research Excerpts

Overview

Fosmidomycin is an effective antimalarial and potent antibiotic. It acts by inhibiting the enzyme 1-deoxy-d-xylulose-5-phosphate reductoisomerase (DXR), essential for the synthesis of isoprenoids in eubacteria and plasmodia, but not in humans.

ExcerptReferenceRelevance
"Fosmidomycin is an effective antimalarial and potent antibiotic, known to act by inhibiting the enzyme 1-deoxy-d-xylulose-5-phosphate reductoisomerase (DXR), essential for the synthesis of isoprenoids in eubacteria and plasmodia, but not in humans."( Synthesis and antimalarial evaluation of prodrugs of novel fosmidomycin analogues.
Barros, MT; Faísca Phillips, AM; Murtinheira, F; Nogueira, F, 2015
)
1.38
"Fosmidomycin is a natural antibiotic with potent IspC (DXR, 1-deoxy-d-xylulose-5-phosphate reductoisomerase) inhibitory activity. "( Acyloxymethyl and alkoxycarbonyloxymethyl prodrugs of a fosmidomycin surrogate as antimalarial and antibacterial agents.
Caljon, G; Coenye, T; Cos, P; Courtens, C; Quennesson, T; Risseeuw, M; Van Calenbergh, S; van Charante, F, 2023
)
2.6
"Fosmidomycin (FOS) is a naturally occurring compound active against the 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) enzyme in the 2-"( Design, Synthesis and Bioactivity Evaluation of Heterocycle-Containing Mono- and Bisphosphonic Acid Compounds.
Bu, M; Duan, J; Wu, X; Yang, Z; Zhang, A, 2023
)
2.35
"Fosmidomycin is a natural antibiotic with promising IspC (DXR, 1-deoxy-d-xylulose-5-phosphate reductoisomerase) inhibitory activity. "( Amino acid based prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents.
Caljon, G; Courtens, C; Maes, L; Martin, A; Risseeuw, M; Van Calenbergh, S, 2019
)
2.24
"Fosmidomycin is an antibiotic that inhibits the second reaction in the nonmevalonate pathway of isoprenoid biosynthesis, an essential pathway for many obligate intracellular pathogens, including mycobacteria and apicomplexan parasites."( Improved efficacy of fosmidomycin against Plasmodium and Mycobacterium species by combination with the cell-penetrating peptide octaarginine.
Amulic, B; Gengenbacher, M; Kamena, F; Kolesinska, B; Matuschewski, K; Purkayastha, N; Seebach, D; Sparr, C, 2013
)
1.43
"Fosmidomycin is a time-dependent nanomolar inhibitor of methylerythritol phosphate (MEP) synthase, which is the enzyme that catalyzes the first committed step in the MEP pathway to isoprenoids. "( Sub-inhibitory fosmidomycin exposures elicits oxidative stress in Salmonella enterica serovar Typhimurium LT2.
Cope, EK; Dhungana, S; Finney, KB; Fox, DT; Koppisch, AT; Leid, JG; Phillips, PD; Schmidt, EN; Testa, CA; Tian, H; Valentine, MC; Warrington, NV, 2014
)
2.2
"Fosmidomycin is a nanomolar inhibitor of DXR, but despite great efforts, few analogues with comparable potency have been developed."( Alteration of the flexible loop in 1-deoxy-D-xylulose-5-phosphate reductoisomerase boosts enthalpy-driven inhibition by fosmidomycin.
Allen, CL; Gulick, AM; Kholodar, SA; Liu, J; Murkin, AS; Tan, Z; Tombline, G, 2014
)
1.33
"Fosmidomycin is an antibacterial and antiparasitic agent that disrupts the isoprenoid biosynthesis pathway, a precursor to hopanoid biosynthesis."( Fosmidomycin decreases membrane hopanoids and potentiates the effects of colistin on Burkholderia multivorans clinical isolates.
Dalleska, NF; Hird, TJ; Lee, TD; Malott, RJ; Newman, DK; Speert, DP; Wu, CH; Zlosnik, JE, 2014
)
2.57
"Fosmidomycin is a phosphonic acid derivative originally isolated as a natural antibiotic from Streptomyces lavendulae. "( A high-throughput colorimetric-based bioassay method for determination of fosmidomycin in plasma and urine and application for pharmacokinetic study.
Cheoymang, A; Na-Bangchang, K,
)
1.8
"Fosmidomycin is a broad-spectrum antimicrobial agent currently in clinical trials of combination therapies for the treatment of malaria."( A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling.
Hicks, LM; Hodge, D; Hunstad, DA; Kemp, LM; Odom, AR; Watts, KM; Zhang, B, 2011
)
1.33
"Fosmidomycin is an effective and safe antimalarial drug, although its use as a single agent is restricted by the occurrence of recrudescent infections."( Fosmidomycin, a novel chemotherapeutic agent for malaria.
Baranek, T; Hintz, M; Hutchinson, D; Jomaa, H; Kremsner, PG; Lell, B; Missinou, MA; Ruangweerayut, R; Schindler, A; Wiesner, J, 2003
)
2.48
"Fosmidomycin is a new antimalarial drug with a novel mechanism of action. "( Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children.
Adegnika, AA; Baranek, T; Borrmann, S; Issifou, S; Jomaa, H; Kremsner, PG; Matsiegui, PB; Mawili-Mboumba, DP; Schindler, A; Wiesner, J, 2004
)
3.21
"Fosmidomycin-clindamycin is a promising novel treatment option for malaria."( Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria.
Adegnika, AA; Borrmann, S; Esser, G; Issifou, S; Jomaa, H; Kremsner, PG; Kun, JF; Matsiegui, PB; Mawili-Mboumba, DP; Missinou, MA; Oyakhirome, S; Ramharter, M, 2004
)
2.49
"Fosmidomycin is a slow tight-binding inhibitor of DXR that shows strong negative cooperativity (absolute value(h) = 0.3) in binding."( A fragment-based approach to understanding inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
Cox, RJ; de Andrés-Gómez, A; Dick, B; Godfrey, CR; Mercklé, L, 2005
)
1.05
"Fosmidomycin is a promising antimalarial drug candidate with a unique chemical structure and a novel mode of action. "( Synthesis and antimalarial activity of chain substituted pivaloyloxymethyl ester analogues of Fosmidomycin and FR900098.
Bergmann, B; Geffken, D; Kaula, U; Kurz, T; Schlüter, K; Walter, RD, 2006
)
2
"Fosmidomycin is a specific inhibitor of the second enzyme of the MEP pathway, 1-deoxy-D-xylulose-5-phosphate reductoisomerase."( Effect of fosmidomycin on metabolic and transcript profiles of the methylerythritol phosphate pathway in Plasmodium falciparum.
Cassera, MB; Katzin, AM; Kimura, EA; Merino, EF; Peres, VJ; Wunderlich, G, 2007
)
1.46
"Fosmidomycin is a phosphonic antibiotic which inhibits 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr), the first committed step of the non-mevalonate pathway of isoprenoid biosynthesis. "( Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake.
Brown, AC; Parish, T, 2008
)
2.04

Treatment

Treatment with fosmidomycin (Fos) or oxoclomazone (OC), inhibitors of the plastidial 2-C-methyl-d-erythritol 4-phosphate (MEP) pathway, caused mislocalization of the protein to the nucleus. Treatment with mevinolin, an inhibitor of the cytosolic mevalonate pathway, did not.

ExcerptReferenceRelevance
"Fosmidomycin treatment caused marked defects in food vacuolar morphology and integrity, consistent with a defect in Rab-mediated vesicular trafficking."( Isoprenoid biosynthesis inhibition disrupts Rab5 localization and food vacuolar integrity in Plasmodium falciparum.
Hodge, D; Howe, R; Jimah, J; Kelly, M; Odom, AR, 2013
)
1.11
"Fosmidomycin-treatment resulted in a decrease of the intermediate levels in the MEP pathway as well as in ubiquinone and dolichol biosynthesis."( Effect of fosmidomycin on metabolic and transcript profiles of the methylerythritol phosphate pathway in Plasmodium falciparum.
Cassera, MB; Katzin, AM; Kimura, EA; Merino, EF; Peres, VJ; Wunderlich, G, 2007
)
1.46
"Treatment with fosmidomycin decreased the MIC of colistin for isolates as much as 64-fold to as low as 8 μg/ml, a concentration achievable with colistin inhalation therapy."( Fosmidomycin decreases membrane hopanoids and potentiates the effects of colistin on Burkholderia multivorans clinical isolates.
Dalleska, NF; Hird, TJ; Lee, TD; Malott, RJ; Newman, DK; Speert, DP; Wu, CH; Zlosnik, JE, 2014
)
2.18
"Treatment with fosmidomycin (Fos) or oxoclomazone (OC), inhibitors of the plastidial 2-C-methyl-d-erythritol 4-phosphate (MEP) pathway, caused mislocalization of the protein to the nucleus, whereas treatment with mevinolin, an inhibitor of the cytosolic mevalonate pathway, did not."( The plastidial 2-C-methyl-D-erythritol 4-phosphate pathway provides the isoprenyl moiety for protein geranylgeranylation in tobacco BY-2 cells.
Bach, TJ; Boronat, A; Crowell, DN; Gerber, E; Hartmann, M; Hartmann, MA; Heintz, D; Hemmerlin, A; Mutterer, J; Rodríguez-Concepción, M; Rohmer, M; Van Dorsselaer, A, 2009
)
0.69

Toxicity

ExcerptReferenceRelevance
" The majority of adverse events affected the gastrointestinal and respiratory tracts and were transient and mild to moderate in severity."( Efficacy and Safety of Fosmidomycin-Piperaquine as Nonartemisinin-Based Combination Therapy for Uncomplicated Falciparum Malaria: A Single-Arm, Age De-escalation Proof-of-Concept Study in Gabon.
Adegnika, AA; Cattaneo, C; Duparc, S; Endamne, L; Flohr, L; Groger, M; Hutchinson, D; Kabwende, L; Kim, J; Kremsner, PG; Lell, B; Lötsch, F; Mischlinger, J; Moehrle, J; Mombo-Ngoma, G; Mordmüller, B; Nguyen, TT; Ramharter, M; Remppis, J; Sievers, M; Velavan, TP; Veletzky, L; Zoleko Manego, R, 2018
)
0.79
" The combination appeared to have high efficacy and be safe and well tolerated despite observed transient changes in electrocardiogram with prolongation of the QT interval."( Efficacy and Safety of Fosmidomycin-Piperaquine as Nonartemisinin-Based Combination Therapy for Uncomplicated Falciparum Malaria: A Single-Arm, Age De-escalation Proof-of-Concept Study in Gabon.
Adegnika, AA; Cattaneo, C; Duparc, S; Endamne, L; Flohr, L; Groger, M; Hutchinson, D; Kabwende, L; Kim, J; Kremsner, PG; Lell, B; Lötsch, F; Mischlinger, J; Moehrle, J; Mombo-Ngoma, G; Mordmüller, B; Nguyen, TT; Ramharter, M; Remppis, J; Sievers, M; Velavan, TP; Veletzky, L; Zoleko Manego, R, 2018
)
0.79

Pharmacokinetics

There were marked differences in the pharmacokinetic profiles of fosmidomycin and clindamycin when given as two different combination regimens. The method appears to be robust and has been applied to a study in a patient with malaria following oral doses of clind amycin at 1200 mg given every 8 h for 7 days.

ExcerptReferenceRelevance
" The method appears to be robust and has been applied to a pharmacokinetic study in plasma and urinary excretion of fosmidomycin in a patient with malaria following oral doses of clindamycin at 1200 mg given every 8 h for 7 days."( Bioassay for determination of fosmidomycin in plasma and urine: application for pharmacokinetic dose optimisation.
Cheoymang, A; Hudchinton, D; Kioy, D; Na-Bangchang, K, 2007
)
0.84
" Blood samples were taken for pharmacokinetic investigations of clindamycin and/or fosmidomycin and 24-hour urine samples were collected during dosing period."( Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria.
Chauemung, A; Hutchinson, D; Karbwang, J; Na-Bangchang, K; Ruengweerayut, R, 2007
)
0.83
"A total of 70 patients with acute uncomplicated Plasmodium falciparum malaria who fulfilled the enrolment criteria were recruited in the pharmacokinetic study."( Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria.
Banmairuroi, V; Chauemung, A; Hutchinson, D; Looareesuwan, S; Na-Bangchang, K; Ruangweerayut, R, 2008
)
0.57
" There were marked differences in the pharmacokinetic profiles of fosmidomycin and clindamycin when given as two different combination regimens."( Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria.
Banmairuroi, V; Chauemung, A; Hutchinson, D; Looareesuwan, S; Na-Bangchang, K; Ruangweerayut, R, 2008
)
0.81
"The analytical method established in this study meets the criteria of high sensitivity, accuracy and reproducibility for routine use in pharmacokinetic studies."( A high-throughput colorimetric-based bioassay method for determination of fosmidomycin in plasma and urine and application for pharmacokinetic study.
Cheoymang, A; Na-Bangchang, K,
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" Here, we investigated whether intracellular delivery of the drug fosmidomycin can be improved by combination with the CPP octaarginine."( Improved efficacy of fosmidomycin against Plasmodium and Mycobacterium species by combination with the cell-penetrating peptide octaarginine.
Amulic, B; Gengenbacher, M; Kamena, F; Kolesinska, B; Matuschewski, K; Purkayastha, N; Seebach, D; Sparr, C, 2013
)
0.95

Bioavailability

ExcerptReferenceRelevance
" The gastrointestinal absorption rate after oral dosing of 500 mg is in general about 20-40%, which can be calculated to be on average about 30% (in comparison with fosfomycin which is on average only about 11%)."( Pharmacokinetic evaluation of fosmidomycin, a new phosphonic acid antibiotic.
De Santis, F; Kuemmerle, HP; Murakawa, T, 1987
)
0.56
" The gastrointestinal absorption rate after oral dosing of 500 mg is in general about 20-40% which can be calculated to be, in average, about 30% (in comparison with fosfomycin which is, in average, about 11% only)."( Fosmidomycin: a new phosphonic acid antibiotic. Part I: Phase I tolerance studies.
Konishi, T; Kuemmerle, HP; Murakawa, T; Soneoka, K, 1985
)
1.71
" The gastrointestinal absorption rate after the oral dosing of 500 mg is in general about 20-40% which can be calculated to be in average about 30% (in comparison with fosfomycin which is in average about 11% only)."( Fosmidomycin, a new phosphonic acid antibiotic. Part II: 1. Human pharmacokinetics. 2. Preliminary early phase IIa clinical studies.
De Santis, F; Konishi, T; Kuemmerle, HP; Murakawa, T; Sakamoto, H; Sato, N, 1985
)
1.71
" The poor efficacy observed for the F/C combination may be a consequence of the new formulations used, differential bioavailability in younger children, naturally occurring variations in parasite sensitivity to the drugs, or an insufficient enhancement of their effects by naturally acquired immunity in young children."( Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria.
Alonso, P; Bassat, Q; Cisteró, P; González, R; Hutchinson, D; Kremsner, PG; Lanaspa, M; Macete, E; Machevo, S; Mayor, A; Menéndez, C; Moraleda, C; Serrano, B, 2012
)
0.64

Dosage Studied

Fosmidomycin was given in combination with clindamycin at two dosage regimens in patients with acute uncomplicated falciparum malaria. Blood samples were taken and 24-hour urine samples collected during dosing period.

ExcerptRelevanceReference
" The gastrointestinal absorption rate after oral dosing of 500 mg is in general about 20-40%, which can be calculated to be on average about 30% (in comparison with fosfomycin which is on average only about 11%)."( Pharmacokinetic evaluation of fosmidomycin, a new phosphonic acid antibiotic.
De Santis, F; Kuemmerle, HP; Murakawa, T, 1987
)
0.56
" The gastrointestinal absorption rate after oral dosing of 500 mg is in general about 20-40% which can be calculated to be, in average, about 30% (in comparison with fosfomycin which is, in average, about 11% only)."( Fosmidomycin: a new phosphonic acid antibiotic. Part I: Phase I tolerance studies.
Konishi, T; Kuemmerle, HP; Murakawa, T; Soneoka, K, 1985
)
1.71
" The gastrointestinal absorption rate after the oral dosing of 500 mg is in general about 20-40% which can be calculated to be in average about 30% (in comparison with fosfomycin which is in average about 11% only)."( Fosmidomycin, a new phosphonic acid antibiotic. Part II: 1. Human pharmacokinetics. 2. Preliminary early phase IIa clinical studies.
De Santis, F; Konishi, T; Kuemmerle, HP; Murakawa, T; Sakamoto, H; Sato, N, 1985
)
1.71
"25 h after dosing was 157 microgram/ml after an intravenous dose of 30 mg/kg, 12."( Pharmacokinetics of fosmidomycin, a new phosphonic acid antibiotic.
Fukada, S; Konishi, T; Murakawa, T; Nishida, M; Sakamoto, H, 1982
)
0.59
" All dosing regimens were well tolerated, and no serious adverse events occurred."( Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria.
Adegnika, AA; Borrmann, S; Esser, G; Issifou, S; Jomaa, H; Kremsner, PG; Kun, JF; Matsiegui, PB; Mawili-Mboumba, DP; Missinou, MA; Oyakhirome, S; Ramharter, M, 2004
)
1.77
" All dosing regimens were well tolerated."( Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria.
Adegnika, AA; Borrmann, S; Esser, G; Hutchinson, D; Issifou, S; Jomaa, H; Kombila, M; Kremsner, PG; Lundgren, I; Matsiegui, PB; Moussavou, F; Oyakhirome, S; Ramharter, M; Wiesner, J, 2005
)
0.6
" The inadequate efficacy in children of <3 years highlights the need for continued systematic studies of the current dosing regimen, which should include randomized trial designs."( Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria.
Adegnika, AA; Borrmann, S; Hutchinson, D; Impouma, B; Issifou, S; Jomaa, H; Kremsner, PG; Kun, JF; Lundgren, I; Matsiegui, PB; Oyakhirome, S; Wiesner, J, 2006
)
1.78
" Blood samples were taken for pharmacokinetic investigations of clindamycin and/or fosmidomycin and 24-hour urine samples were collected during dosing period."( Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria.
Chauemung, A; Hutchinson, D; Karbwang, J; Na-Bangchang, K; Ruengweerayut, R, 2007
)
0.83
"This study investigated the pharmacokinetics of fosmidomycin when given in combination with clindamycin at two dosage regimens in patients with acute uncomplicated falciparum malaria."( Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria.
Banmairuroi, V; Chauemung, A; Hutchinson, D; Looareesuwan, S; Na-Bangchang, K; Ruangweerayut, R, 2008
)
0.83
" Patients were treated with two different dosage regimens of fosmidomycin in combination with clindamycin as follows:Group I: fosmidomycin (900 mg) and clindamycin (300 mg) every 6 hours for 3 days (n = 25); and Group II: fosmidomycin (1,800 mg) and clindamycin (600 mg) every 12 hours for 3 days (n = 54)."( Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria.
Banmairuroi, V; Chauemung, A; Hutchinson, D; Looareesuwan, S; Na-Bangchang, K; Ruangweerayut, R, 2008
)
0.81
"37 microg/ml), resulting in significantly higher fluctuations in the plasma concentrations of both fosmidomycin and clindamycin following multiple dosing (110."( Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria.
Banmairuroi, V; Chauemung, A; Hutchinson, D; Looareesuwan, S; Na-Bangchang, K; Ruangweerayut, R, 2008
)
0.79
"The findings may suggest that dosing frequency and duration have a significant impact on outcome."( Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria.
Banmairuroi, V; Chauemung, A; Hutchinson, D; Looareesuwan, S; Na-Bangchang, K; Ruangweerayut, R, 2008
)
0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitorAn EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (EC 1.1.1.267).
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phosphonic acidsHP(=O)(OH)2 (phosphonic acid) and its P-substituted derivatives.
hydroxamic acidA compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
1-deoxy-D-xylulose 5-phosphate reductoisomeraseMycolicibacterium smegmatis MC2 155IC50 (µMol)0.29500.08000.59751.4800AID653488; AID653489
1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12IC50 (µMol)231.65420.02000.74213.5000AID1163707; AID1179058; AID1801044; AID243156; AID263162; AID263367; AID275057; AID553590
1-deoxy-D-xylulose 5-phosphate reductoisomeraseMycobacterium tuberculosis H37RvIC50 (µMol)0.16500.08000.41892.3900AID1063497; AID358110; AID605839; AID617056; AID762065; AID773740
1-deoxy-D-xylulose 5-phosphate reductoisomeraseMycobacterium tuberculosis H37RvKi0.14000.13000.13500.1400AID605762
1-deoxy-D-xylulose 5-phosphate reductoisomeraseSynechocystis sp. PCC 6803 substr. KazusaKi0.02100.02100.02100.0210AID238735
1-deoxy-D-xylulose 5-phosphate reductoisomerase, chloroplasticArabidopsis thaliana (thale cress)IC50 (µMol)0.10000.10000.10000.1000AID1113112
1-deoxy-D-xylulose 5-phosphate reductoisomerase Escherichia coliIC50 (µMol)0.43800.22000.32900.4380AID1203541
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
1-deoxy-D-xylulose 5-phosphate reductoisomeraseMycobacterium tuberculosis H37RvKd0.04000.04000.04000.0400AID762067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
isoprenoid biosynthetic process1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway involved in terpenoid biosynthetic process1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway involved in terpenoid biosynthetic process1-deoxy-D-xylulose 5-phosphate reductoisomerase, chloroplasticArabidopsis thaliana (thale cress)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
oxidoreductase activity1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
manganese ion binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
1-deoxy-D-xylulose-5-phosphate reductoisomerase activity1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
identical protein binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
metal ion binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
NADPH binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
1-deoxy-D-xylulose-5-phosphate reductoisomerase activity1-deoxy-D-xylulose 5-phosphate reductoisomerase, chloroplasticArabidopsis thaliana (thale cress)
manganese ion binding1-deoxy-D-xylulose 5-phosphate reductoisomerase, chloroplasticArabidopsis thaliana (thale cress)
NADPH binding1-deoxy-D-xylulose 5-phosphate reductoisomerase, chloroplasticArabidopsis thaliana (thale cress)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
Dxr protein complex1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (164)

Assay IDTitleYearJournalArticle
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID553588Half life in plasma2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Structures of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase/Lipophilic Phosphonate Complexes.
AID762065Inhibition of Mycobacterium tuberculosis DXR using DXP as substrate assessed as formation of MEP measured every 5 secs for 180 secs by spectrophotometric analysis2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
DXR inhibition by potent mono- and disubstituted fosmidomycin analogues.
AID605762Inhibition of Mycobacterium tuberculosis recombinant DXR expressed in Escherichia coli BL21 (DE3) using DXP as substrate and MgCl2 as cofactor preincubated for 10 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.
AID441922Antibacterial activity against Escherichia coli B/r after 24 hrs by NCCLS method2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID673979Inhibition of Escherichia coli DXR using DXP as substrate preincubated for 5 mins2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID620076Inhibition of Plasmodium falciparum IspC2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID497719Inhibition of IPTG-stimulated Escherichia coli K-12 tolC at 16 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID275061Antibacterial activity against Escherichia coli K122006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID497742Inhibition of IPTG-stimulated Escherichia coli K-12 glxK at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID497885Inhibition of IPTG-stimulated Escherichia coli K-12 tolC at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID725846Inhibition of Plasmodium falciparum recombinant DXR using DXP as substrate preincubated for 5 mins2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Antimalarial and Structural Studies of Pyridine-containing Inhibitors of 1-Deoxyxylulose-5-phosphate Reductoisomerase.
AID482242Antiplasmodial activity against Plasmodium berghei ANKA infected in mice (Mus musculus) assessed as suppression of parasitaemia at 50 mg/kg, intraperitoneal for 5 consecutive days measured on day 4 post parasitic infection2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Synthesis and evaluation of alpha-halogenated analogues of 3-(acetylhydroxyamino)propylphosphonic acid (FR900098) as antimalarials.
AID1113112Inhibition of Arabidopsis thaliana IspC expressed in Escherichia coli after 40 min by spectrophotometric analysis2013Pest management science, May, Volume: 69, Issue:5
In search of new herbicidal inhibitors of the non-mevalonate pathway.
AID1197864Antiplasmodial activity against blood stage forms of chloroquine-sensitive Plasmodium falciparum 3D7 incubated for 3 days by HRP2 detection based ELISA method2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Prodrugs of reverse fosmidomycin analogues.
AID1077487Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 2 weeks2013MedChemComm, Jul-01, Volume: 4, Issue:7
Design of Potential Bisubstrate Inhibitors against
AID497740Inhibition of IPTG-stimulated Escherichia coli K-12 baeR at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1163707Inhibition of Escherichia coli Dxr2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Development of inhibitors of the 2C-methyl-D-erythritol 4-phosphate (MEP) pathway enzymes as potential anti-infective agents.
AID1203543Antibacterial activity against Escherichia coli ATCC 8739 by two-fold broth microdilution method2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Synthesis and bioactivity of β-substituted fosmidomycin analogues targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID632322Antibacterial activity against Bacillus anthracis after overnight incubation by microbroth dilution method2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID620080Cytotoxicity against human MRC5 cells2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr).
AID482237Antiplasmodial activity against Plasmodium falciparum K1 by micro dilution assay2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Synthesis and evaluation of alpha-halogenated analogues of 3-(acetylhydroxyamino)propylphosphonic acid (FR900098) as antimalarials.
AID632326Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by microbroth dilution method2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.
AID695972Inhibition of Escherichia coli recombinant His6-tagged DXR expressed in Escherichia coli XL-1 blue using DXP as substrate after 5 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Modifications around the hydroxamic acid chelating group of fosmidomycin, an inhibitor of the metalloenzyme 1-deoxyxylulose 5-phosphate reductoisomerase (DXR).
AID1195270Antimalarial activity against chloroquine and mefloquine-resistant Plasmodium falciparum Dd2 after 48 hrs by SYBR Green I assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Synthesis and antimalarial evaluation of prodrugs of novel fosmidomycin analogues.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID497880Inhibition of IPTG-stimulated Escherichia coli K-12 rplB at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID497729Inhibition of IPTG-stimulated Escherichia coli K-12 tolC at 8 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1077492Inhibition of His-tagged Mycobacterium tuberculosis DXR expressed in Escherichia coli BL21(DE3) using DXP as substrate assessed as oxidation of NADPH preincubated for 10 mins followed by NADPH and substrate addition by spectrophotometric analysis2013MedChemComm, Jul-01, Volume: 4, Issue:7
Design of Potential Bisubstrate Inhibitors against
AID620077Inhibition of Escherichia coli IspC2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1063497Inhibition of Mycobacterium tuberculosis Dxr2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs.
AID1334846Growth inhibition of Mycobacterium smegmatis incubated overnight by paper disc diffusion method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis and biological evaluation of phosphate isosters of fosmidomycin and analogs as inhibitors of Escherichia coli and Mycobacterium smegmatis 1-deoxyxylulose 5-phosphate reductoisomerases.
AID632329Antibacterial activity against Escherichia coli expressing TolC after overnight incubation by microbroth dilution method2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.
AID605839Inhibition of Mycobacterium tuberculosis recombinant DXR expressed in Escherichia coli BL21 (DE3) using DXP as substrate and Mn2+ as cofactor preincubated for 10 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.
AID1625280Antimalarial activity against Plasmodium vinckei infected in po dosed mouse assessed as reduction in parasitemia administered tid by 4-day suppression test2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID275054Antibacterial activity against Escherichia coli W31102006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID358109Inhibition of Escherichia coli DXR by spectrophotometric method2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
Structures of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase provide new insights into catalysis.
AID725848Antimalarial activity against Plasmodium falciparum Dd2 after 3 days by SYBR green I assay2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Antimalarial and Structural Studies of Pyridine-containing Inhibitors of 1-Deoxyxylulose-5-phosphate Reductoisomerase.
AID497906Inhibition of IPTG-stimulated Escherichia coli K-12 ddlB at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID620078Ratio of IC50 for Escherichia coli IspC to IC50 for Plasmodium falciparum IspC2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr).
AID322181Inhibition of Escherichia coli DXR2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.
AID263163Inhibition of Plasmodium falciparum Dd22006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent Plasmodium falciparum growth inhibitors.
AID275063Ratio, MIC/MBC for Escherichia coli K122006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID653489Inhibition of Mycobacterium smegmatis DSM 43756 ATCC 19420 N-terminal his-tagged DXR expressed in XL1-blue Escherichia coli using NADPH and DXP as substrate preincubated for 2 mins with substrate before compound addition2012European journal of medicinal chemistry, May, Volume: 51Growth inhibition of Mycobacterium smegmatis by prodrugs of deoxyxylulose phosphate reducto-isomerase inhibitors, promising anti-mycobacterial agents.
AID605840Half life in plasma2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.
AID673985Binding affinity to Escherichia coli DXR by isothermal titration colorimetric assay in presence of 2 mM NADPH and 150 mM NaCl at 279 K and pH 7.6 and Mn2+2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase.
AID725845Antimalarial activity against Plasmodium falciparum 3D7 after 3 days by SYBR green I assay2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Antimalarial and Structural Studies of Pyridine-containing Inhibitors of 1-Deoxyxylulose-5-phosphate Reductoisomerase.
AID497889Inhibition of IPTG-stimulated Escherichia coli K-12 murA at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID322182Antimalarial activity against Plasmodium falciparum 3D7 in infected human erythrocytes after 48 hrs2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.
AID497747Inhibition of IPTG-stimulated Escherichia coli K-12 murD at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID275056Antibacterial activity against Escherichia coli pTMV19 in presence of mevalonate2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID1203546Antibacterial activity against Mycobacterium smegmatis ATCC 607 after 24 to 48 hrs by two-fold broth microdilution method2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Synthesis and bioactivity of β-substituted fosmidomycin analogues targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID725844Half life in plasma (unknown origin)2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Antimalarial and Structural Studies of Pyridine-containing Inhibitors of 1-Deoxyxylulose-5-phosphate Reductoisomerase.
AID497884Inhibition of IPTG-stimulated Escherichia coli K-12 rpmB at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1203544Antibacterial activity against Escherichia coli ATCC 25922 by two-fold broth microdilution method2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Synthesis and bioactivity of β-substituted fosmidomycin analogues targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID762070Inhibition of Plasmodium falciparum DXR using DXP as substrate measured every 5 secs for 250 secs in presence of NADPH2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
DXR inhibition by potent mono- and disubstituted fosmidomycin analogues.
AID497745Inhibition of IPTG-stimulated Escherichia coli K-12 dapB at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID605760Inhibition of Escherichia coli recombinant DXR using DXP as substrate and MgCl2 as cofactor preincubated for 10 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.
AID1193736Antimalarial activity against MRA-150, chloroquine, pyrimethamine, mefloquine-resistant asexual blood stage Plasmodium falciparum Dd2 assessed as rescue at 10 uM after 72 hrs by SYBR green assay in presence of 200 uM IPP2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Determination of the active stereoisomer of the MEP pathway-targeting antimalarial agent MMV008138, and initial structure-activity studies.
AID1197863Antiplasmodial activity against blood stage forms of multidrug-resistant Plasmodium falciparum Dd2 incubated for 3 days by HRP2 detection based ELISA method2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Prodrugs of reverse fosmidomycin analogues.
AID275055Antibacterial activity against Escherichia coli pTMV192006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID1334839Growth inhibition of Escherichia coli XL1 blue at 2 nmol/disc incubated overnight by paper disc diffusion method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis and biological evaluation of phosphate isosters of fosmidomycin and analogs as inhibitors of Escherichia coli and Mycobacterium smegmatis 1-deoxyxylulose 5-phosphate reductoisomerases.
AID620146Antimalarial activity against Plasmodium berghei ANKA infected in Swiss mouse assessed as suppression of infected RBC at 40 mg/kg, ip bid for 5 days coadministered with ritonavir 10 mg/kg, po2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr).
AID617056Inhibition of Mycobacterium tuberculosis DXR assessed as reduction of 1-deoxy-D-xylulose 5-phosphate into 2-C-methyl-D-erythritol-4-phosphate measured for every 5 secs upto 500 secs by spectrophotometry analysis2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Substitution of the phosphonic acid and hydroxamic acid functionalities of the DXR inhibitor FR900098: an attempt to improve the activity against Mycobacterium tuberculosis.
AID1193734Antimalarial activity against MRA-150, chloroquine, pyrimethamine, mefloquine-resistant asexual blood stage Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Determination of the active stereoisomer of the MEP pathway-targeting antimalarial agent MMV008138, and initial structure-activity studies.
AID632323Antibacterial activity against Enterococcus faecalis after overnight incubation by microbroth dilution method2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.
AID482246Antiplasmodial activity against Plasmodium berghei ANKA infected in mice (Mus musculus) assessed as mice (Mus musculus) survival at 50 mg/kg, intraperitoneal for 5 consecutive days measured on day 7 post parasitic infection2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Synthesis and evaluation of alpha-halogenated analogues of 3-(acetylhydroxyamino)propylphosphonic acid (FR900098) as antimalarials.
AID482251Antiplasmodial activity against Plasmodium berghei ANKA infected in mice (Mus musculus) assessed as mean survival time at 50 mg/kg, intraperitoneal for 5 consecutive days2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Synthesis and evaluation of alpha-halogenated analogues of 3-(acetylhydroxyamino)propylphosphonic acid (FR900098) as antimalarials.
AID1197862Inhibition of recombinant Plasmodium falciparum IspC using [3,4,5-13C3]1-Deoxy-D-xylulose 5-phosphate substrate by photometric assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Prodrugs of reverse fosmidomycin analogues.
AID497744Inhibition of IPTG-stimulated Escherichia coli K-12 yrbB at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID358110Inhibition of Mycobacterium tuberculosis DXR assessed as NADPH-dependent conversion of 1-deoxy-D-xylulose 5-phosphate to 2-C-methyl-D-erythritol 4-phosphate by spectrophotometric method2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
Structures of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase provide new insights into catalysis.
AID632327Antibacterial activity against Acinetobacter after overnight incubation by microbroth dilution method2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.
AID553589Antimalarial activity against Plasmodium falciparum2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Structures of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase/Lipophilic Phosphonate Complexes.
AID263164Inhibition of Plasmodium falciparum 3D72006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent Plasmodium falciparum growth inhibitors.
AID762067Binding affinity to Mycobacterium tuberculosis DXR assessed as dissociation constant by spectrofluorimetric analysis in presence of NADPH and MnCl22013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
DXR inhibition by potent mono- and disubstituted fosmidomycin analogues.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID497882Inhibition of IPTG-stimulated Escherichia coli K-12 ftsX at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1179058Inhibition of His-tagged Escherichia coli DXR pre-incubated for 2 mins before reaction initiation in presence of 160 uM NADPH in absence of 0.01% Triton X1002014Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14
Catechol-rhodanine derivatives: Specific and promiscuous inhibitors of Escherichia coli deoxyxylulose phosphate reductoisomerase (DXR).
AID673984Binding affinity to Mycobacterium tuberculosis DXR by isothermal titration colorimetric assay in presence of 2 mM NADPH and 150 mM NaCl at 279 K and pH 7.62012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase.
AID673982Binding affinity to His6-tagged Plasmodium falciparum DXR expressed in Escherichia coli M15 by isothermal titration colorimetric assay in presence of 2 mM NADPH and 150 mM NaCl at 279 K and pH 7.62012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID773740Inhibition of Mycobacterium tuberculosis IspC by photometric assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
IspC as target for antiinfective drug discovery: synthesis, enantiomeric separation, and structural biology of fosmidomycin thia isosters.
AID275057Inhibition of Escherichia coli DXR2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID238735Binding affinity against Synechocystis strain PCC6803 DXP reductoisomerase2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Substrate analogs for the investigation of deoxyxylulose 5-phosphate reductoisomerase inhibition: synthesis and evaluation.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1625284Oral bioavailability in rat2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID263367Inhibition of recombinant Escherichia coli DXR2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors.
AID673981Inhibition of His6-tagged Plasmodium falciparum DXR expressed in Escherichia coli M15 using DXP as substrate preincubated for 5 mins2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID725847Inhibition of Escherichia coli recombinant DXR using DXP as substrate preincubated for 5 mins2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Antimalarial and Structural Studies of Pyridine-containing Inhibitors of 1-Deoxyxylulose-5-phosphate Reductoisomerase.
AID441923Antibacterial activity against Pseudomonas aeruginosa H45006 after 24 hrs by NCCLS method2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1203541Inhibition of recombinant Escherichia coli Dxr expressed in Escherichia coli BL21 CodonPlus (DE3)-RIL cells using DOXP as substrate assessed as NADPH oxidation preincubated for 5 mins with NADPH followed by substrate addition by spectrophotometric analysi2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Synthesis and bioactivity of β-substituted fosmidomycin analogues targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID762072Inhibition of Escherichia coli DXR using DXP as substrate measured every 5 secs for 250 secs in presence of NADPH2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
DXR inhibition by potent mono- and disubstituted fosmidomycin analogues.
AID632324Antibacterial activity against methicillin-susceptible Staphylococcus aureus after overnight incubation by microbroth dilution method2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.
AID1203542Inhibition of recombinant Plasmodium falciparum Dxr expressed in Escherichia coli C43(DE3) using DOXP as substrate assessed as NADPH oxidation by spectrophotometric analysis2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Synthesis and bioactivity of β-substituted fosmidomycin analogues targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID441924Antibacterial activity against Bacillus anthracis Sterne after 24 hrs by NCCLS method2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID1625279Antimalarial activity against Plasmodium vinckei infected in ip dosed mouse assessed as reduction in parasitemia administered tid by 4-day suppression test2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID243156Inhibitory concentration against DOXP reductoisomerase2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
AFMoC enhances predictivity of 3D QSAR: a case study with DOXP-reductoisomerase.
AID497715Inhibition of IPTG-stimulated Escherichia coli K-12 dxr at 16 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1203545Antibacterial activity against Escherichia coli K-12 by two-fold broth microdilution method2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Synthesis and bioactivity of β-substituted fosmidomycin analogues targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID673980Binding affinity to Escherichia coli DXR by isothermal titration colorimetric assay in presence of 2 mM NADPH and 150 mM NaCl at 279 K and pH 7.6 and Mg2+2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase.
AID497746Inhibition of IPTG-stimulated Escherichia coli K-12 tmk at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID497883Inhibition of IPTG-stimulated Escherichia coli K-12 hemA at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID620147Antimalarial activity against Plasmodium berghei ANKA infected in Swiss mouse assessed as survival at 40 mg/kg, ip bid for 5 days coadministered with ritonavir 40 mg/kg, po2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr).
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID441920Inhibition of Escherichia coli M15 DXR2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID695976Ratio of IC50 for Escherichia coli recombinant His6-tagged DXR without preincubation to IC50 for Escherichia coli recombinant His6-tagged DXR with preincubation2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Modifications around the hydroxamic acid chelating group of fosmidomycin, an inhibitor of the metalloenzyme 1-deoxyxylulose 5-phosphate reductoisomerase (DXR).
AID673988Binding affinity to Escherichia coli DXR by isothermal titration colorimetric assay in presence of 2 mM NADPH and 150 mM NaCl at 279 K and pH 8.5 and Mg2+2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID497890Inhibition of IPTG-stimulated Escherichia coli K-12 cca at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID497725Inhibition of IPTG-stimulated Escherichia coli K-12 dxr at 8 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID497881Inhibition of IPTG-stimulated Escherichia coli K-12 mesJ at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID722448Antimalarial activity against Plasmodium falciparum 3D7 assessed as parasite growth inhibition2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Alpha-heteroatom derivatized analogues of 3-(acetylhydroxyamino)propyl phosphonic acid (FR900098) as antimalarials.
AID632328Antibacterial activity against Escherichia coli K-12 after overnight incubation by microbroth dilution method2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.
AID263369Antimalarial activity against Plasmodium falciparum 3D72006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID568987Inhibition of Escherichia coli DXR assessed as conversion of NADPH to NADP at 0.3 uM by spectrophotometry2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Synthesis and evaluation of phosphonated N-heteroarylcarboxamides as DOXP-reductoisomerase (DXR) inhibitors.
AID275058Inhibition of Trypanosoma brucei FPPS expressed in Escherichia coli2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID497748Inhibition of IPTG-stimulated Escherichia coli K-12 umpA at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1334844Growth inhibition of fosmidomycin resistant Escherichia coli incubated overnight by paper disc diffusion method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis and biological evaluation of phosphate isosters of fosmidomycin and analogs as inhibitors of Escherichia coli and Mycobacterium smegmatis 1-deoxyxylulose 5-phosphate reductoisomerases.
AID497743Inhibition of IPTG-stimulated Escherichia coli K-12 fadl at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID497886Inhibition of IPTG-stimulated Escherichia coli K-12 yjeE at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID673983Inhibition of Mycobacterium tuberculosis DXR using DXP as substrate preincubated for 5 mins2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID441925Antibacterial activity against Micrococcus luteus WT after 24 hrs by NCCLS method2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID308577Inhibition of Escherichia coli DXR2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of alpha,beta-unsaturated alpha-aryl-substituted fosmidomycin analogues as DXR inhibitors.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1197865Antiplasmodial activity against blood stage forms of chloroquine-sensitive Plasmodium falciparum D10 incubated for 3 days by HRP2 detection based ELISA method2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Prodrugs of reverse fosmidomycin analogues.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID695974Inhibition of Escherichia coli recombinant His6-tagged DXR expressed in Escherichia coli XL-1 blue using DXP as substrate incubated for 2 mins prior to substrate addition measured after 5 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Modifications around the hydroxamic acid chelating group of fosmidomycin, an inhibitor of the metalloenzyme 1-deoxyxylulose 5-phosphate reductoisomerase (DXR).
AID738622Inhibition of recombinant Toxoplasma gondii DXR catalytic domain (68 to 513) expressed in Escherichia coli BL21 using DXP as substrate after 10 mins by Uv-spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Expression, characterization and inhibition of Toxoplasma gondii 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID553590Inhibition of Escherichia coli DXR2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Structures of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase/Lipophilic Phosphonate Complexes.
AID497716Inhibition of IPTG-stimulated Escherichia coli K-12 ydiL at 16 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID263162Inhibition of recombinant Escherichia coli DXR2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent Plasmodium falciparum growth inhibitors.
AID497741Inhibition of IPTG-stimulated Escherichia coli K-12 ydfW at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID607182Inhibition of Mycobacterium tuberculosis DXR-catalyzed NADPH-dependent rearrangement and reduction of DXP to form MEP measured every 5 secs for 500 secs by spectrophotometric analysis2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Design, synthesis, and X-ray crystallographic studies of α-aryl substituted fosmidomycin analogues as inhibitors of Mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
AID730756Inhibition of N-terminal His6-tagged Escherichia coli DXR after 2 mins in presence of NADPH2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Synthesis of tetrazole analogues of phosphonohydroxamic acids: an attempt to improve the inhibitory activity against the DXR.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID497750Inhibition of IPTG-stimulated Escherichia coli K-12 dxr at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID497726Inhibition of IPTG-stimulated Escherichia coli K-12 ydiL at 8 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1334837Inhibition of Escherichia coli His6-tagged DXR preincubated for 2 mins in presence of NADPH followed by DXP substrate addition2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis and biological evaluation of phosphate isosters of fosmidomycin and analogs as inhibitors of Escherichia coli and Mycobacterium smegmatis 1-deoxyxylulose 5-phosphate reductoisomerases.
AID275059Antibacterial activity against Escherichia coli K12 by broth microdilution method2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID632325Antibacterial activity against methicillin-resistant Staphylococcus aureus after overnight incubation by microbroth dilution method2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.
AID263368Antimalarial activity against Plasmodium falciparum Dd22006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors.
AID620079Antimicrobial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as inhibition of parasite replication2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr).
AID497879Inhibition of IPTG-stimulated Escherichia coli K-12 yefM at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1625278Antimalarial activity against Plasmodium falciparum Dd2 assessed as reduction in parasite viability by [3H]-hypoxanthine incorporation assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID1203547Antibacterial activity against Mycobacterium smegmatis ATCC 700084 after 24 to 48 hrs by two-fold broth microdilution method2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Synthesis and bioactivity of β-substituted fosmidomycin analogues targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
AID497749Inhibition of IPTG-stimulated Escherichia coli K-12 mreC at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID653492Antimycobacterial activity against Mycobacterium smegmatis at 400 nmol/disc after 24 hrs by paper disc diffusion method2012European journal of medicinal chemistry, May, Volume: 51Growth inhibition of Mycobacterium smegmatis by prodrugs of deoxyxylulose phosphate reducto-isomerase inhibitors, promising anti-mycobacterial agents.
AID773741Inhibition of Escherichia coli IspC by photometric assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
IspC as target for antiinfective drug discovery: synthesis, enantiomeric separation, and structural biology of fosmidomycin thia isosters.
AID653488Inhibition of Mycobacterium smegmatis DXR2012European journal of medicinal chemistry, May, Volume: 51Growth inhibition of Mycobacterium smegmatis by prodrugs of deoxyxylulose phosphate reducto-isomerase inhibitors, promising anti-mycobacterial agents.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1801044DXR Inhibition Assay for Fosmidomycin from Article 10.1016/j.bioorg.2015.02.008: \\Flavonoids: true or promiscuous inhibitors of enzyme? The case of deoxyxylulose phosphate reductoisomerase.\\2015Bioorganic chemistry, Apr, Volume: 59Flavonoids: true or promiscuous inhibitors of enzyme? The case of deoxyxylulose phosphate reductoisomerase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (235)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (6.81)18.7374
1990's3 (1.28)18.2507
2000's92 (39.15)29.6817
2010's109 (46.38)24.3611
2020's15 (6.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.97 (24.57)
Research Supply Index5.54 (2.92)
Research Growth Index5.77 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (4.12%)5.53%
Reviews20 (8.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other213 (87.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicentre Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in African Children [NCT01361269]Phase 2100 participants (Anticipated)Interventional2011-06-30Not yet recruiting
Evaluation of Fosmidomycin and Clindamycin When Administered Concurrently to Adult Subjects With Acute Uncomplicated Plasmodium Falciparum Malaria [NCT01002183]Phase 240 participants (Anticipated)InterventionalWithdrawn(stopped due to Drug combination is no longer pursued)
A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria [NCT02198807]Phase 2100 participants (Actual)Interventional2014-03-31Active, not recruiting
A Comparative Assessment of the Efficacy of Fosmidomycin-Clindamycin Versus Sulfadoxine-Pyrimethamine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria [NCT00214643]Phase 3160 participants Interventional2005-06-30Completed
Evaluation of Fosmidomycin in Combination With Clindamycin in Children With Acute Uncomplicated Plasmodium Falciparum Malaria [NCT00217451]Phase 251 participants Interventional2002-06-30Completed
Evaluation of Fosmidomycin and Azithromycin When Administered Concurrently to Adult Subjects With Acute Uncomplicated Plasmodium Falciparum Malaria [NCT01464125]Phase 243 participants (Actual)Interventional2008-11-30Active, not recruiting
Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children [NCT01464138]Phase 252 participants (Actual)Interventional2010-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]